gestalt, great post. yes, clearly we could have approval right now, were it not for the Amarex debacle. water under the bridge at this point.

do you think, (i) given that we now have some cash in the bank AND (ii) have an experienced (and i belive) well respected leader, that we're well positioned to capitalize on the potential value here? In other words, positioned to navigate past this regulatory stuff, avoid selling out for less than we are worth, and transmit the majority of the potential value of this molecule to shareholders?

i believe that we are, and am willing to wait longer. but curious on how you see things following the raise, and following Cyrus now coming on board.